The Committee for Medicinal Products for Human Use of the EMA approved the cancer therapies Cejemly for metastatic NSCLC and Avzivi, a bevacizumab biosimilar for various cancers. Cejemly showed positive results in clinical trials and will be available as an infusion. Avzivi has similar efficacy and safety to Avastin and is approved for multiple cancer types. Additionally, five generic cancer medicines, including Apexelsin for breast, pancreatic, and lung cancer, and Pomalidomide for multiple myeloma, were recommended for approval. These medications act on various mechanisms to inhibit tumor growth and are expected to provide additional treatment options for cancer patients.
Source link
EMA Panel Nods to Seven New Cancer Drugs
